Introduction
espite steady progress in treatment of cardiovascular diseases, people are still dying of these diseases, although at later ages. 1 By the year 2020, Coronary heart disease (CHD) and stroke will hold first and fourth places respectively in the World Health Organization's list of leading causes of disability. 2 Smoking, obesity, hypercholesterolaemia, family history, physical inactivity, diabetes mellitus, hypertension are established risk factors of IHD. In recent years, it has been suggested that one half to two thirds of risk for atherosclerotic vascular disease can be explained by classic risk factors. 3 
Prospective cohort studies:
Prospective longitudinal studies provided a strong and consistent association between a risk factor and disease is found. However, the results of prospective cohort studies that evaluated the association between hyperhomocysteinaemia and vascular risk remained inconclusive.
A large prospective cohort study from Trömsø, Norway, reported a relative risk for coronary artery disease of 1.41 (CI, 1.16 to 1.71) for each increase of 4 µmol/L in serum Hcy level. 12 After 5 years of follow up, the physicians Health Study found an adjusted relative risk for fatal or nonfatal myocardial infarction of 3.4 (CI, 1.3 to 8.8; p=0.01) for persons whose Hcy levels were in the highest 5% compared with those whose Hcy levels were in the lowest 90%. 12 The British United Provident Association study reported a risk for fatal coronary heart disease of 2.9 (CI, 2.04 to 4.12) among men whose Hcy level was in the highest quarter compared with those whose Hcy level was in the lowest quarter, after adjustment for other risk factors. 13 The British Regional Heart Study found an independent, graded, positive association between hyperhomocysteinemia and the risk for stroke.
14 Plasma Hcy levels seemed to be the strongest predictor of mortality in a prospective study of patients with angiographically confirmed coronary artery disease and previous myocardial infarction. The risk of death (compared with a plasma Hcy level of < 9 µmol/L) was 1.9 for patients with Hcy level between 9 and 14.9 µmol/L, and 4.5 for Hcy levels of more than 20 µmol/L. 15 A smaller prospective study from Zutphen, Netherlands, reported a positive association between Hcy levels and risk for myocardial infarction and stroke. 16 The Rotterdam study reported odds ratio of 2.53 (CI, 1.19 to 5.35) for stroke and 2.43 (CI, 1.11 to 5.35) for myocardial infarction in patients whose plasma Hcy level was in the highest fifth. 17 Schnyder et al observed significant association of t-Fcy with the severity of CAD (p <0.05) along with other established risk factors. 18 A study conducted in 2001 in Bangladeshi population showed that plasma homocysteine level is significantly higher in CAD patients than control subjects (p = 0.001). 19 In a recent study (in 2003) at National Institute of Cardiovascular Diseases (NICVD), Dhaka, an attempt was made to find out the association between plasma total homocysteine level and the number of major epicardial coronary arteries severely narrowed. A total of 100 patients admitted for coronary angiography, with the diagnosis of ischaemic heart disease, in National Institute of Cardiovascular Diseases, Dhaka, Bangladesh, in 2003, were included in this study. Amongst them 50 patients were taken as cases (Fasting plasma total homocysteine level > 15 µ mol/ l) and 50 patients were taken as control (Fasting plasma total homocysteine level < 15 µmol/l). The patients in both study and control groups were similar in respect to their age, gender and BMI, and had similar distribution of risk factors for CAD. Only tHcy was heigher in study group. Coronary angiogram was reviewed to identify culprit lesions and >50% stenosis was regarded as significant. Disease severity was evaluated by counting the major epicardial coronary arteries with significant stenosis. This study showed significant association of homocysteine level with the severity of CAD (p < 0.001). In our study homocysteine level levels were 10.6 ± 1.82 (µmol/l) in the group with 0-vessel disease and 17.62 ± 4.8 (µmol/l) in the group with 3-vessel disease. 20 
Conclusion
Raised plasma total homocysteine level seems to have a significant positive correlation with the pathogenesis of ischaemic heart disease. It may also be regarded as an independent risk factor for this disease. Raised plasma total homocysteine level also seems to have significant positive correlation with the number of vessel involvement in established coronary artery disease. Hyperhomocysteinaemia thus may predict whether early interventional or a more conservative approach of therapy would provide maximum benefit to the patient. However, further research involving a large number of participants is expected to substantiate the pathophysiologic findings of the current studies. 
